Teva to buy Cephalon
Teva Pharmaceutical Industries Ltd. plans to acquire Cephalon Inc. in a $6.8 billion cash deal. The pharmaceutical companies said Monday that the $81.50-per-share acquisition agreement, pending regulatory and shareholder approvals, is expected to close in the third quarter.